FIELD: biochemistry.
SUBSTANCE: invention relates to a boron-containing compound of formula (I) or a pharmaceutically acceptable salt or stereoisomer thereof: (I). In formula (I), L is a bond, -CR1R2-, >C=O, or =CR1-; M is a bond or -N (R4)-; m is 0 or 1; n is 0 or 1; with the proviso that when n is 0, then M is a bond; p equals 1 or 2; X1 is -OH; Z is >C=O; CycA is cyclobutane, cyclopentane or cyclohexane; Ra, Rb and Rc represent a hydrogen atom; each R1 and R2 is independently selected from the group consisting of a hydrogen atom, C1-C6-alkyl and -NR4R5, R3 is hydrogen atom; Rd is selected from the group consisting of a hydrogen atom and C1-C6 alkyl; each R4 and R5 is independently selected from the group consisting of a hydrogen atom, C1-C6-alkyl, 3-6-membered cycloalkyl, 3-6-membered heterocyclyl, 5-6-membered heteroaryl, C1-C6 alkyl(3-6-membered cycloalkyl) and C1-C6 alkyl(5-6 membered heteroaryl); or R4 and R5, taken together, form a 3-6 membered heterocycle with a nitrogen atom, to which they are attached; each R6 and R7 is independently selected from the group consisting of a hydrogen atom, C1-C6 alkyl, -OH, -SR10, -NR4R5, -NR4C(O)OR5, -C(O)OR5 and -NR4SO2R5; each R10 is independently C1-C6-alkyl; and each Y is independently selected from the group consisting of -OH, -NR4R5, -(CR6R7)vNR4R5, -NR4(CR6R7)vNR4R5, -N(R4)C(O)(CR6R7)vNR4R5, -(CR6R7)vN(R4)C(O)(CR6R7)vNR4R5, -NR5C(O)NR4(CR6R7)vNR4R5, -N(R4)C(=NR5)R6, -(CR6R7)vN(R4)C(=NR5)NR4R5, -NR4(CR6R7)vN(R4)C(=NR5)NR4R5, -NR4C(=NR5)NR4R5, -(CR6R7)vNR4(CR6R7)vNR4R5, -NR4(CR6R7)vR6, -NR4(CR6R7)vNR4(CR6R7)vNR4R5, -(3-6-membered heterocyclyl) NR4R5, -(3-6-membered heterocyclyl)N(R4)C(=NR5)NR4R5, -NR4(CR6R7)v(5-6 membered heteroaryl), -NR4(CR6R7)v-(3-6-membered heterocyclyl), -NR4(CR6R7)vNR5-(5-6-membered heteroaryl) and -NR4(CR6thR7th)v-(3-6-membered heterocyclyl)-C(=NR5)NR4R5; and v is 1, 2, or 3. Pharmaceutical composition and a method of treating a bacterial infection are also provided.
EFFECT: compound of formula (I) is used to treat a bacterial infection.
25 cl, 108 ex, 4 tbl, 38 outlines
Title | Year | Author | Number |
---|---|---|---|
BETA-LACTAMASE INHIBITORS | 2015 |
|
RU2686740C2 |
BORONIC ACID DERIVATIVES | 2018 |
|
RU2793315C2 |
MAGL INHIBITORS | 2017 |
|
RU2754536C1 |
METHODS AND COMPOSITIONS FOR INDUCING APOPTOSIS OF CANCER CELLS | 2003 |
|
RU2379056C2 |
AZABICYCLO-QUINOLONE CAROBOXYLIC ACIDS OR THEIR PHARMACEUTICALLY ACCEPTABLE ACID-ADDITIVE SALTS AND INTERMEDIATE PRODUCTS FOR THEIR SYNTHESIS | 1989 |
|
RU2049777C1 |
5-HT- AND D-RECEPTOR DOUBLE MODULATORS | 2008 |
|
RU2480466C2 |
PROTEOLYSIS MODULATORS AND RELATED USES | 2019 |
|
RU2805511C2 |
3-OXO-3,9-DIHYDRO-1H-CHROMENO[2,3-c] PYRROLES AS GLUCOKINASE ACTIVATORS | 2011 |
|
RU2603191C2 |
PYRIDINE DERIVATIVES CONDENSED WITH HETEROCYCLE | 1996 |
|
RU2136683C1 |
DERIVATIVES OF BETA-AMINO ACID NITRILES | 2001 |
|
RU2245871C2 |
Authors
Dates
2018-05-22—Published
2013-12-05—Filed